So on the basis of a transaction value of 4* peak revenue that's ~28bn USD, which if assuming USD-AUD exchange of 0.7, equates to ~40bn AUD, or roughly 300 times current market cap, I think ~$250 AUD a share.
This is why people feel ludicrous talking about the numbers. Still, got to get there first and plenty of commercial/execution risk.
And Dr T has mentioned the assumptions in that report are on the conservative side. Wonder how this compares to the largest ever acquisition of a biomed stock on the ASX.
So on the basis of a transaction value of 4* peak revenue that's...
-
- There are more pages in this discussion • 4,471 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |